Application of steroid compound

Abstract

The invention provides an application of a steroid compound in preparation of products for preventing or treating skin pigmentation related conditions or anti-aging related conditions, the steroid compound is shown as a formula (I), and the steroid compound has treatment, fading and / or relieving effects on age pigments, freckles, chloasma and the like generated by pigmentation on skin of mammals. # imgabs0 #

Description

Application of steroid compounds Technical Field

[0001] The present invention belongs to the field of chemical technology, and particularly relates to the use of a steroid compound in preparing a product for preventing or treating skin pigmentation-related conditions. Background Art

[0002] Melanin is a general term for a class of compounds found in animals, plants, and protozoa. In the human body, melanin is formed in melanosomes, which are cellular structures found in cells called melanocytes. Melanocytes are located in the lowermost layer of the epidermis, basal layer, and basal cells. Melanin is transported to the keratinocytes in the stratum corneum of the skin via the keratinocytes of the epidermis and imparts a brown pigment to the stratum corneum of the skin. Due to the presence of melanin in the stratum corneum of the skin, melanin is responsible for the pigmentation of human skin. Melanin can absorb ultraviolet radiation, thereby playing an important role in protecting the human body (particularly skin) from the damage and potential carcinogenic effects of other environmental sources of sunlight and ultraviolet radiation. When exposed to ultraviolet radiation, the human body naturally increases the production of melanin in the exposed skin area as a defense mechanism. The increased production of melanin causes the exposed skin color to darken, a phenomenon commonly referred to as tanning. Hyperpigmentation and other uneven skin pigmentation symptoms are generally considered to be undesirable and unsightly. The pigmentation of skin of the present invention is characterized by the presence of dark spots on the face or other parts of the body.For example, the generation of acne, rash, scratch or damage of skin can cause inflammatory post-pigmentation, and is characterized by the presence of unwanted dark spots on the face or other parts of the body. Melasma is the condition of illness relevant to the hormonal changes caused by pregnancy, taking birth control pills or menopausal changes, and it is usually covered by the pigment deposited on the surface of the epidermis or the deeper pigment of the dermis. Pigmentation spot is also referred to as liver spot, is the dark discoloration caused by sun damage, and it generally occurs in the older individuality. Freckles are small spots common in young people with fair skin, and such skin is easy to be sunburned when exposed to sunlight.

[0003] Senile plaques (SS) or Senile Plaques (SP) are one of the most visible signs of aging in mammalian skin. They form gradually on the skin's surface due to the continuous deposition of lipofuscin, a pigment produced by aging, in skin cells and sweat glands. They are most common in the elderly. Senile plaques are flat, oval-shaped, brownish-black, tan, or dark-brown spots or plaques that appear on the face, back of the hands, arms, and even the body. They are most common on the scalp and face, followed by the back of the hands, neck, chest, back, and limbs.

[0004] There are four main mechanisms for the development of age spots. First, with aging, pigment accumulates in human cells and is deposited on the skin's surface, forming age spots. Second, it is caused by factors such as genetic inheritance. This is an autosomal dominant skin condition, most commonly found on the face, especially around the nose and cheeks. Because the lesions resemble the spots left by bird pecks or fowl eggs, they are also called freckles. Third, it is related to free radicals. With aging, the production of free radicals by metabolic processes in human cells gradually increases. When the body's ability to scavenge free radicals decreases, these chemically active free radicals react rapidly and cause severe damage. Of these, the attack of oxygen free radicals on lipid membranes is most closely linked to the appearance of age spots. These free radicals oxidize unsaturated fatty acids into peroxides, which can further decompose to produce large amounts of aldehydes, alcohols, and hydrocarbons. Among them, malondialdehyde has strong biological toxicity and can easily react with phospholipid proteins to form the age-related pigment lipofuscin. Fourthly, it is related to physical factors such as ultraviolet radiation. Long-term, large-scale, and continuous ultraviolet radiation can cause epidermal cells to produce singlet oxygen, superoxide radicals, hydroxyl radicals and other reactive oxygen species. These can not only damage the 8-hydroxyguanosine of DNA and cause genetic mutations, but also produce or accelerate epidermal lipid peroxidation to form lipofuscin or age spots. In addition to sunlight exposure, air pollution, radiation, ozone, etc. will promote the formation of free radicals, accelerating the formation of age spots on the skin.

[0005] Currently, the main treatments for age spots include the following: First, pay attention to diet, eat more fruits and vegetables, and supplement vitamin C to promote blood circulation and metabolism, regulate hormone secretion, enhance skin cell vitality, and prevent the formation of skin lipofuscin and age spots. Second, physical therapy, such as electrocautery, laser therapy, and methods such as high-frequency current application / freezing / cutting / grinding. Third, chemotherapy, which uses chemical peels to destroy the skin's surface, causing it to form a scab, and then fall off to achieve the therapeutic purpose, such as using 33% trichloroacetic acid solution. This method must be strictly followed according to the doctor's instructions. Fourth, biotechnology, such as superoxide dismutase (SOD) preparations and SOD complex enzyme (SOD-CCE) systems, metallothionein (MT), and activated protective proteins, can scavenge free radicals in the body and prevent the formation of lipofuscin. Fifth, traditional Chinese medicine treatment. Traditional Chinese medicine for removing lipofuscin currently mainly uses single herbs, compound herbs, or Chinese patent medicines with significant antioxidant effects, free radical and metabolite scavenging properties, and increased content of large-molecule free radical scavengers and SOD activity.

[0006] Analysis reveals that the above products still have many shortcomings. For example, although physical therapy is effective and has immediate results, it can easily burn the skin and leave permanent scars. It also requires multiple, long-term treatments and must be completed by skilled and experienced practitioners in professional medical institutions, and is expensive. Chemotherapy can cause certain damage to the skin's stratum corneum, causing skin side effects. Biological and traditional Chinese medicine therapies can only temporarily prevent or delay the formation of pigments such as melanin or lipofuscin, and cannot achieve the desired therapeutic effect.

[0007] Therefore, there is an urgent need on the market for a convenient and practical product that can prevent or treat skin pigmentation-related conditions.

[0008] Summary of the Invention

[0009] In view of the shortcomings of the existing technology, the purpose of the present invention is to provide a steroid compound for use in a product for preventing or treating pigmentation-related conditions. The steroid compound provided by the present invention can have a good therapeutic, mitigating and preventive effect on age spots, and can greatly reduce and / or cure age spots.

[0010] To achieve this object, the present invention adopts the following technical solutions:

[0011] In a first aspect, the present invention provides a steroidal compound for use in preventing or treating skin pigmentation-related conditions or anti-aging-related products, wherein the steroidal compound is a compound having a structure as shown in Formula I, or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt, or prodrug of the compound having a structure as shown in Formula I;

[0012] wherein R is H, D (deuterium), alkyl, sulfate, phosphate, alkylsilyl, benzyl, or -C(O)-X;

[0013] X is selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroalkyl or alkyl;

[0014] The aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroalkyl, alkylsilyl and alkyl groups in R and X are optionally substituted with 1, 2, 3 or 4 substituents which are the same or different;

[0015] The substituent is selected from D, halogen, hydroxyl, thiol, amino, cyano, nitro, carboxyl, alkylcarbonyl, alkyl, haloalkyl, cycloalkyl, heterocyclic, aryl, arylalkyl, heteroaryl, carboxyl, R 1 R 2 NC(=O)- or R 1 R 2 NC(=NH)-NR 3 -;

[0016] R1 、R 2 and R 3 Each is independently selected from -H, -D or alkyl.

[0017] In some embodiments, the steroidal compound is a compound having a structure as shown in Formula II, or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of a compound having a structure as shown in Formula II;

[0018] wherein R is defined as in formula (I).

[0019] In some embodiments, R is H, D, C 1-6 Alkyl, sulfate, phosphate, C 1-6 Alkylsilyl, benzyl or -C(O)-X.

[0020] In some embodiments, X is selected from C 6-10 Aryl, C 2-9 Heteroaryl, C 3-8 Cycloalkyl, C 2-10 Heterocyclic group, C 1-6 Heteroalkyl or C 1-6 alkyl.

[0021] In some embodiments, the C 6-10 Aryl, C 2-9 Heteroaryl, C 3-8 Cycloalkyl, C 2-10 Heterocyclic group, C 1-6 Heteroalkyl, C 1-6 Alkylsilyl or C 1-6 The alkyl group is optionally substituted with 1, 2, 3 or 4 substituents which may be the same or different.

[0022] In some embodiments, the substituent is selected from D, halogen, hydroxyl, thiol, amino, cyano, nitro, carboxyl, C 1-6 Alkylcarbonyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl, C 2-10 Heterocyclic group, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 2-9 Heteroaryl, carboxyl (e.g. -COOH), R 1 R 2 NC(=O)- or R 1 R 2 NC(=NH)-NR 3 -.

[0023] In some embodiments, R 1 、R 2 and R 3 Each independently selected from -H, -D or C 1-6 alkyl.

[0024] In some embodiments, X is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, mercaptoethyl, aminomethyl, aminoethyl, aminopropyl, phenylmethyl, phenylethyl, imidazolylmethyl, carboxymethyl, carboxyethyl, methylthiomethyl, methylthioethyl, phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, dithiolanyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, furanyl, imidazolyl, 3-isoxazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl, tetrazolyl, triazolyl, 2-thienyl, 3-thienyl, pyrazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl, 1,3,5- triazinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, indolyl, purinyl, quinolyl, isoquinolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, C with H2NC(=O)-substituent 1-3 Alkyl or C with H2NC(=NH)-NH-substituent 1-3 alkyl.

[0025] In some embodiments, the substituents in R and X are selected from -H, -D, halogen, hydroxy, amino, cyano, nitro, carboxyl, C 1-6 Alkylcarbonyl, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, C 2-9 Heterocyclic group, C 6-10Aryl or C 2-9 Heteroaryl.

[0026] In other embodiments, the substituents in R and X are selected from -H, -D, -F, -Cl, -Br, hydroxyl, amino, cyano, carboxyl, formyl, acetyl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, trifluoromethyl, difluoromethyl, phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, disulfide pentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, furanyl, imidazolyl, 3-isoxazole yl, isoxazolyl, oxazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl, tetrazolyl, triazolyl, 2-thienyl, 3-thienyl, pyrazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl, 1,3,5-triazinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, indolyl, purinyl, quinolinyl, isoquinolinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl or [1,2,4]triazolo[1,5-a]pyridinyl.

[0027] As a specific embodiment of the present invention, X is selected from any of the following groups:

[0028] As a specific embodiment of the present invention, the compound represented by the structure of Formula I or II is selected from any one of the following compounds:

[0029] In some embodiments, the product is a pharmaceutical, a skin care product, or a health product.

[0030] In some embodiments, the skin pigmentation-related condition is selected from one or more of melasma, chloasma, leucoderma, age spots, café au lait spots, and freckles.

[0031] In some embodiments, the anti-aging product is an anti-skin aging product.

[0032] In some embodiments, the product is in the form of a solution, emulsion, suspension, cream, ointment, gel, or patch.

[0033] The steroid compound provided by the present invention can be used as an unprocessed chemical drug for treatment, or can be provided as an active ingredient of a pharmaceutical composition.

[0034] In a second aspect, the present invention provides a composition for use in preparing a product for preventing or treating skin pigmentation-related conditions or anti-aging-related products, wherein the composition comprises the steroid compound described in the first aspect, and one or more pharmaceutically or cosmetically acceptable carriers, excipients, diluents, adjuvants or vehicles.

[0035] Substances that can be used as pharmaceutically or cosmetically acceptable carriers include, but are not limited to, ion exchangers; aluminum; aluminum stearate; lecithin; serum albumin, such as human serum albumin; buffer substances such as phosphates; glycine; sorbic acid; potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water; salts; electrolytes such as protamine sulfate; disodium hydrogen phosphate; potassium hydrogen phosphate; sodium chloride; zinc salts; colloidal silicon; magnesium trisilicate; polyvinyl pyrrolidone; polyacrylates; waxes; polyethylene glycol; Polyoxypropylene-blocking polymers; lanolin; sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; gum powder; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycol compounds such as propylene glycol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol, phosphate buffered solution, and other non-toxic suitable lubricants such as sodium lauryl sulfate and magnesium stearate, colorants, release agents, coatings, sweeteners, flavorings and fragrances, preservatives and antioxidants.

[0036] In some embodiments, the product is a pharmaceutical, a skin care product, or a health product.

[0037] In some embodiments, the skin pigmentation-related condition is selected from one or more of melasma, chloasma, leucoderma, age spots, café au lait spots, and freckles.

[0038] In some embodiments, the anti-aging product is an anti-skin aging product.

[0039] In some embodiments, the product is in the form of a solution, emulsion, suspension, cream, ointment, gel, or patch.

[0040] In a third aspect, the present invention provides a method for preventing or treating skin pigmentation-related conditions or anti-aging, comprising administering to a subject the steroid compound described in the first aspect (a compound having a structure as shown in Formula I or Formula II, or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of a compound having a structure as shown in Formula I or Formula II) or the composition described in the second aspect.

[0041] In some embodiments, the skin pigmentation-related condition is selected from one or more of melasma, chloasma, leucoderma, age spots, café au lait spots, and freckles.

[0042] In some embodiments, the anti-aging product is an anti-skin aging product.

[0043] Compared with the prior art, the present invention has the following beneficial effects:

[0044] The present invention has found that the steroid compound provided by the present invention can be used to prevent, treat, cure or alleviate age spots, freckles or chloasma etc. of patients, and is convenient and practical with little side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] FIG1 is a facial photograph of a patient on the 1st day and the 60th day after application of the composition of the present invention. DETAILED DESCRIPTION

[0046] The technical solution of the present invention is further described below by way of specific embodiments. It should be understood by those skilled in the art that the specific embodiments are merely to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0047] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0048] As used herein, "stereoisomers" refer to compounds that have the same chemical structure but differ in the spatial arrangement of atoms or groups. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like.

[0049] Depending on the choice of starting materials and process, the compounds of the present invention may exist as one of the possible isomers or as a mixture thereof, such as a racemate or a mixture of diastereoisomers (depending on the number of asymmetric carbon atoms). Optically active (R)- or (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration; if the compound contains a disubstituted cycloalkyl group, the cycloalkyl substituents may be in the cis or trans configuration.

[0050] Any resulting mixture of stereoisomers can be separated into the pure or substantially pure geometric isomers, enantiomers, and diastereomers on the basis of the differences in the constituent physicochemical properties, for example, by chromatography and / or fractional crystallization.

[0051] Unless otherwise indicated, the structural formulae described herein include all isomeric forms (e.g., enantiomers, diastereomers, and geometric isomers (or conformers): for example, R and S configurations containing asymmetric centers, (Z) and (E) isomers of double bonds, and (Z) and (E) conformers. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers, or geometric isomers (or conformers) are within the scope of the present invention.

[0052] The term "prodrug" as used in the present invention refers to a compound that is converted into a compound represented by Formula I or Formula II in vivo. Such conversion is affected by the prodrug being hydrolyzed in the blood or being converted into the parent structure by enzymes in the blood or tissues. The prodrug compound of the present invention may be an ester. In the prior art, esters that can be used as prodrugs include phenyl esters, aliphatic (C 1-24) esters, acyloxymethyl esters, carbonates, carbamates, and amino acid esters. For example, a compound of the present invention containing a hydroxyl group can be acylated to produce a prodrug form of the compound. Other prodrug forms include phosphate esters, such as these phosphate ester compounds, which are obtained by phosphorylating a hydroxyl group on the parent compound. For a complete discussion of prodrugs, see T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, J. Rautio et al, Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and SJ Hecker et al, Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry, 2008, 51, 2328-2345.

[0053] Any racemate of the resulting final product or intermediate can be resolved into its optical antipodes by methods familiar to those skilled in the art using known methods, such as by separation of its diastereomeric salts obtained. Racemic products can also be separated by chiral chromatography, such as high performance liquid chromatography (HPLC) using a chiral adsorbent. In particular, enantiomers can be prepared by asymmetric synthesis, for example, see Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Principles of Asymmetric Synthesis (2nd Ed. Robert E. Gawley, Jeffrey Aubé, Elsevier, Oxford, UK, 2012); Eliel, EL Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SH Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972); Chiral Separation Techniques: A Practical Approach (Subramanian, G. Ed., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2007).

[0054] The term "tautomer" or "tautomeric form" refers to structural isomers with different energies that are interconvertible via a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol isomerizations and imine-enamine isomerizations. Valence tautomers include interconversions via reorganization of some of the bonding electrons. A specific example of keto-enol tautomerism is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerism is phenol-keto tautomerism. A specific example of phenol-keto tautomerism is the interconversion of pyridin-4-ol and pyridin-4(1H)-one tautomers. Unless otherwise indicated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention.

[0055] The salts mentioned in the present invention are pharmaceutically acceptable salts, wherein "pharmaceutically acceptable salts" are well known in the art, as described in the literature: Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmacol Sci, 1997, 66, 1-19. Non-limiting examples of pharmaceutically acceptable salts include inorganic acid salts formed by reaction with an amino group, such as hydrochlorides, hydrobromides, phosphates, metaphosphates, sulfates, sulfites, nitrates, and perchlorates, and organic acid salts, such as carboxylates, sulfonates, sulfinates, and thiocarboxylates, specifically, but not limited to, methanesulfonates, ethanesulfonates, formates, acetates, succinates, benzoates, succinates, pamoates, salicylates, galactarates, glucoheptanoates, mandelates, 1,2-ethanedisulfonates, 2-naphthalenesulfonates, carbonates, trifluoroacetates, glycolates, isethionates, oxalates, maleates, tartrates, citrates, succinates, malonates, benzenesulfonates, p-toluenesulfonates, malates, fumarates, lactates, lactobionates, or oxalates, or such salts may be obtained by other methods described in the literature, such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentylpropionate, digluconate, dodecylsulfate, ethanesulfonate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, laurate, lauryl sulfate, nicotinate, nitrate, oleate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, stearate, thiocyanate, undecanoate, valerate, etc. In addition, pharmaceutically acceptable salts also include salts obtained with appropriate bases, such as alkali metal, alkaline earth metal, ammonium and N + (C 1-4 The present invention also contemplates quaternary ammonium salts formed by any compound containing a N group. Water-soluble or oil-soluble or dispersible products can be obtained by quaternization. Alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Pharmaceutically acceptable salts further include appropriate, non-toxic ammonium, quaternary ammonium salts and amine cations formed by counter ions, such as halides, carboxylates, sulfates, phosphates, nitrates, C 1-8 Sulfonates and aromatic sulfonates.

[0056] Pharmaceutically acceptable salts can be formed with inorganic and organic acids, for example, acetate, aspartate, benzoate, benzenesulfonate, bromide / hydrobromide, bicarbonate / carbonate, bisulfate / sulfate, camphorsulfonate, chloride / hydrochloride, chlorophylline, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hippurate, hydroiodide / iodide, isethionate, lactate, lactobionate, lauryl sulfate, malate, maleate, malonate, mandelate, methanesulfonate, methylsulfate, naphthoate, naphthylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, polygalactonate, propionate, stearate, succinate, sulfosalicylate, tartrate, toluenesulfonate, and trifluoroacetate.

[0057] Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.

[0058] Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, sulfosalicylic acid, and the like.

[0059] As used herein, a "solvate" refers to an association formed between one or more solvent molecules and a compound of the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol. The term "hydrate" refers to an association formed when the solvent molecule is water.

[0060] A "composition" refers to a mixture of one or more compounds, salts, or physiologically / pharmaceutically acceptable salts or prodrugs thereof described herein with other chemical components, such as physiologically / pharmaceutically acceptable carriers or excipients. The purpose of a composition is to facilitate administration of the compound to an organism.

[0061] As used herein, the term "treating" any disease or condition, in some embodiments, refers to ameliorating the disease or condition (i.e., slowing or arresting or alleviating the development of the disease or at least one clinical symptom thereof). In other embodiments, "treating" refers to alleviating or improving at least one physical parameter, including physical parameters that may not be perceived by the patient. In other embodiments, "treating" refers to regulating the disease or condition physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a physical parameter), or both. In other embodiments, "treating" refers to preventing or delaying the onset, occurrence, or worsening of a disease or condition.

[0062] As used herein, the term "alkyl" refers to a saturated, linear or branched, monovalent hydrocarbon radical of 1 to 20 carbon atoms, or 1 to 10 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 4 carbon atoms, or 1 to 3 carbon atoms, wherein the alkyl radical may be independently and optionally substituted with one or more substituents described herein. Examples of alkyl radicals include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl (t-Bu, -CH(CH3)CH2CH3), ... -C(CH3)3), n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1- Butyl (-CH2CH(CH3)CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3 ), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, and the like. The term "alkyl" and its prefix "alkane" as used herein include both straight and branched saturated carbon chains. The term "alkylene" as used herein refers to a saturated divalent hydrocarbon radical derived from a straight or branched saturated hydrocarbon by eliminating two hydrogen atoms, examples of which include, but are not limited to, methylene, ethylene, isopropylidene, and the like.

[0063] The term "cycloalkyl" refers to a monovalent or polyvalent, non-aromatic, saturated or partially unsaturated ring containing no heteroatoms, including a monocyclic ring of 3-12 carbon atoms or a bicyclic ring of 7-12 carbon atoms. Bicyclic carbocycles having 7-12 atoms may be bicyclic [4,5], [5,5], [5,6], or [6,6] systems, while bicyclic carbocycles having 9 or 10 atoms may be bicyclic [5,6] or [6,6] systems. Suitable cyclic aliphatic groups include, but are not limited to, cycloalkyl, cycloalkenyl, and cycloalkynyl groups. Examples of cyclic aliphatic groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-enyl, 1-cyclopentyl-2-enyl, 1-cyclopentyl-3-enyl, cyclohexyl, 1-cyclohexyl-1-enyl, 1-cyclohexyl-2-enyl, 1-cyclohexyl-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like. And the "cyclic aliphatic group" or "carbocycle", "carbocyclyl", "cycloalkyl" may be substituted or unsubstituted, wherein the substituents may be, but are not limited to, hydroxy, amino, halogen, cyano, aryl, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, thiol, nitro, aryloxy, hydroxy-substituted alkoxy, hydroxy-substituted alkyl-C(=O), alkyl-C(=O), alkyl-S(=O), alkyl-S(=O)2-, hydroxy-substituted alkyl-S(=O), hydroxy-substituted alkyl-S(=O)2, carboxyalkoxy, etc.

[0064] The terms "heterocycle," "heterocyclyl," "heteroalicyclic," or "heterocyclic" are used interchangeably herein and refer to a monocyclic, bicyclic, or tricyclic ring system in which one or more carbon atoms in the ring(s) are independently and optionally replaced by heteroatoms, wherein the heteroatoms have the meanings herein, the ring(s) may be fully saturated or contain one or more degrees of unsaturation, but are never aromatic, and have only one point of attachment to another molecule. One or more hydrogen atoms in the ring(s) are independently and optionally replaced by one or more substituents as described herein. In some embodiments, the "heterocycle", "heterocyclyl", "heteroalicyclic" or "heterocyclic" group is a 3-7 membered monocyclic ring (1-6 carbon atoms and 1-3 heteroatoms selected from N, O, P, S, wherein S or P is optionally replaced by one or more oxygen atoms to give groups such as SO, SO2, PO, PO2, and when the ring is a three-membered ring, there is only one heteroatom therein), or a 7-10 membered bicyclic ring (4-9 carbon atoms and 1-3 heteroatoms selected from N, O, P, S, wherein S or P is optionally replaced by one or more oxygen atoms to give groups such as SO, SO2, PO, PO2).

[0065] Heterocyclic groups can be carbon groups or heteroatom groups. "Heterocyclic group" also includes groups formed by the combination of a heterocyclic group with a saturated or partially unsaturated ring or heterocyclic ring. Examples of heterocyclic rings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, thiazolidinyl, oxazolidinyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, piperidinyl, homopiperidinyl, glycidyl, azepanyl, oxetanyl, thiepanyl, 4-methoxy-piperidin-1-yl, 1,2,3,6-tetrahydropyridin-1-yl, oxazepine Base, diazepine Base, thiazolin yl, pyrrolin-1-yl, 2-pyrrolin-1-yl, 3-pyrrolin-1-yl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxane, 1,3-dioxolane, pyrazolinyl, dithianyl, dithiolanyl, dihydrothienyl, pyrazolidinylimidazolinyl, imidazolidinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,6-thiadiazinane 1,1-dioxol-2-yl, 4-hydroxy-1,4-azaphosphane 4-oxide-1-yl, 2-hydroxy-1-(piperazin-1-yl)ethanone-4-yl, 2-hydroxy-1-(5,6-dihydro-1,2,4-triazin-1(4H)-yl)ethanone-4-yl, 5,6-dihydro-4 H-1,2,4-oxadiazin-4-yl, 2-hydroxy-1-(5,6-dihydropyridin-1(2H)-yl)ethan-4-yl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[4.1.0]heptyl, azabicyclo[2.2.2]hexyl, 2-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-c]pyrimidin-6-yl, 4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridin-5-yl, 3H-indolyl, 2-oxo-5-azabicyclo[2.2.1]heptan-5-yl, 2-oxo-5-azabicyclo[2.2.2]octan-5-yl, quinolizinyl and N-pyridylurea. Examples of heterocyclic groups also include 1,1-dioxothiomorpholinyl, and pyrimidinedione in which two carbon atoms in the ring are replaced by oxygen atoms. The heterocyclic group may be substituted or unsubstituted, and the substituents may be, but are not limited to, oxo (=O), hydroxy, amino, halogen, cyano, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, alkynyl, heterocyclic group, mercapto, nitro, aryloxy, hydroxy-substituted alkoxy, hydroxy-substituted alkyl-C (=O), alkyl-C (=O), alkyl-S (=O), alkyl-S (=O) 2-, hydroxy-substituted alkyl-S (=O), hydroxy-substituted alkyl-S (=O) 2, carboxyalkoxy, and the like.

[0066] The term "aryl" can be used alone or as part of "aralkyl," "aralkoxy," or "aryloxyalkyl" to refer to monocyclic, bicyclic, and tricyclic carbocyclic ring systems containing a total of 6-14 ring members, wherein at least one ring system is aromatic, wherein each ring system contains 3-7 ring members, and has only one point of attachment to the rest of the molecule. The term "aryl" can be used interchangeably with the term "aromatic ring," and aromatic rings can include, for example, phenyl, naphthyl, and anthracenyl. And the aryl group may be substituted or unsubstituted, wherein the substituents may be, but are not limited to, hydroxy, amino, halogen, cyano, aryl, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, alkynyl, heterocyclyl, thiol, nitro, aryloxy, hydroxy-substituted alkoxy, hydroxy-substituted alkyl-C(=O), alkyl-C(=O), alkyl-S(=O), alkyl-S(=O)2-, hydroxy-substituted alkyl-S(=O), hydroxy-substituted alkyl-S(=O)2, carboxyalkoxy, and the like.

[0067] The term "heteroaryl" refers to monocyclic, bicyclic, and tricyclic ring systems containing a total of 5-14 ring members, wherein at least one ring system is aromatic and at least one ring system contains one or more heteroatoms, wherein the heteroatoms have the meanings herein, and wherein each ring system contains 3-7 ring members and has only one point of attachment to the rest of the molecule. The term "heteroaryl" may be used interchangeably with the terms "heteroaromatic" or "heteroaromatic compound." And the heteroaryl group may be substituted or unsubstituted, wherein the substituents may be, but are not limited to, hydroxy, amino, halogen, cyano, aryl, heteroaryl, alkoxy, alkylamino, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, thiol, nitro, aryloxy, hydroxy-substituted alkoxy, hydroxy-substituted alkyl-C(=O)-, alkyl-C(=O)-, alkyl-S(=O)-, alkyl-S(=O)2-, hydroxy-substituted alkyl-S(=O)-, hydroxy-substituted alkyl-S(=O)2-, carboxyalkoxy and the like.

[0068] In other embodiments, heteroaryl includes, but is not limited to, the following monocyclic rings: 2-furyl, 3-furyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 4-methylisoxazol-5-yl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, pyrimidin-5-yl, pyridazinyl (such as 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (such as 5-tetrazolyl), triazolyl (such as 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (such as 2-pyrazolyl), ), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, 1,3,4-thiadiazol-2-yl, pyrazinyl, pyrazin-2-yl, 1,3,5-triazinyl; also includes the following dioxadiazolyl ring, but is in no way limited to these bicyclic rings: benzimidazolyl, benzofuranyl, benzothiophenyl, indolyl (such as 2-indolyl), purinyl, quinolyl (such as 2-quinolyl, 3-quinolyl, 4-quinolyl), and isoquinolyl (such as 1-isoquinolyl, 3-isoquinolyl or 4-isoquinolyl), benzo[d]thiazol-2-yl, imidazo[1,5-a]pyridin-6-yl.

[0069] The term "heteroatom" means one or more O, S, N, P and Si atoms, including N, S and P in any oxidation state; in the form of primary, secondary, tertiary amines and quaternary ammonium salts; or in the form of a nitrogen atom in a heterocyclic ring in which the hydrogen is substituted, for example, N (e.g., N in 3,4-dihydro-2H-pyrrolyl), NH (e.g., NH in pyrrolidinyl) or NR (e.g., NR in N-substituted pyrrolidinyl).

[0070] The term "heteroalkyl" means that one or more heteroatoms may be inserted into the middle of the alkyl chain, wherein the alkyl group and heteroatom have the meanings as described herein. Unless otherwise specified, the heteroalkyl group contains 1-10 carbon atoms, in other embodiments, the heteroalkyl group contains 1-8 carbon atoms, in other embodiments, the heteroalkyl group contains 1-6 carbon atoms, in other embodiments, the heteroalkyl group contains 1-4 carbon atoms, and in other embodiments, the heteroalkyl group contains 1-3 carbon atoms. Such examples include, but are not limited to, CH3OCH2-, CH3CH2OCH2-, CH3SCH2-, CH3SCH2CH2-, (CH3)2NCH2-, (CH3)2CH2OCH2-, CH3OCH2CH2-, CH3CH2OCH2CH2-, etc.

[0071] The term "halogen" refers to F, Cl, Br or I.

[0072] The term "halogenated" used in the present invention means that the group following it is substituted with halogen, and the number of substitutions can be one or more.

[0073] The term "hydroxy-substituted" used in the present invention means that the group following it is substituted with a hydroxyl group, and the number of substitutions may be one or more.

[0074] When "substituted" in the present invention is used between two groups, it is preceded by a substituent, such as "aryl-substituted alkyl" means that the alkyl group has an aryl substituent, and "alkoxycarbonyl-substituted alkyl" means that the alkyl group has an alkoxycarbonyl substituent.

[0075] When multiple groups of the present invention are used in combination, they are in a substitution relationship from left to right, such as "arylalkyl" represents an alkyl substituted by an aryl group, and "alkoxyalkoxy" represents an alkoxy substituted by an alkoxy group.

[0076] As used herein, the term "skin" is intended to include the skin on the face, neck, chest, back, arms (including the underarms), hands, legs, buttocks, and scalp.

[0077] The synthesis of the compounds in the present invention was obtained by referring to the method described in WO 2018137683.

[0078] Example 1 Tyrosinase inhibition test

[0079] The test steps are as follows:

[0080] 1) Primary human melanocytes were seeded into 6-well plates and cultured in melanocyte growth medium (MGM) supplemented with human melanocyte growth supplements for 18-24 hours.

[0081] 2) The original culture medium was removed, and culture medium containing different concentrations (1 μM, 5 μM, 10 μM, 25 μM) of the compound 1 of the present invention was added and cultured for 24 h;

[0082] 3) After exposure, remove the culture medium, wash twice with PBS, and collect cells from each well using a cell scraper. Centrifuge at 10,000 rpm / min at 4°C to collect cells.

[0083] 4) Add cell lysis buffer, perform repeated freeze-thaw cycles to lyse the cells, and centrifuge at 10,000 rpm / min at 4°C for 20 min to obtain the supernatant;

[0084] 5) Add the supernatant from each group to a 96-well plate, quickly add the L-DOPA solution, shake, and measure the absorbance at 475 nm. Incubate at 37°C for 30 minutes, then measure the absorbance again.

[0085] 6) Statistical methods

[0086] Graphs were generated using Graph Pad Prism, and the results are expressed as mean ± SD. Statistical analysis was performed using the t-test for multiple comparisons between groups. All statistical analyses were two-tailed. P < 0.05 was considered significant, with *p < 0.05, 0.005 < **p < 0.01, and ***p < 0.001 being considered significant. Smaller p values ​​indicate significant differences.

[0087] The compound 1 used in step 2) is

[0088] Conclusion: The test results show that the compounds of the present invention have a certain inhibitory effect on tyrosinase.

[0089] Example 2 Melanoderm test

[0090] The control compounds consisted of a negative control (ultrapure water), a vehicle control [dimethyl sulfoxide (DMSO) in ultrapure water - a final concentration of 0.1%] and a positive control (2% kojic acid in ultrapure water - a final concentration of 700 μM). The test compounds of the present invention were prepared in DMSO at a concentration of 10 mM and diluted to a final concentration of 10 μM with EPI-100-LLMM culture medium (Mattek Corp.). Melanin model human tissue (MEL-300-B, Mattek Corp.) was balanced with EPI-100-NMM culture medium for 24 hours, followed by 48 hours with EPI-100-LLMM culture medium, and then treated with test compounds of the present invention and controls. According to the standard protocol, the melanin model was administered with controls and test compounds of the present invention for a total of 12 days, and the melanin model was collected for melanin quantification, vitality analysis, and macroscopic / microscopic imaging analysis. For melanin quantification, the tissue was suspended in phosphate buffered saline (PBS) buffer (5 ml) for 5 minutes, removed from PBS and washed / rinsed with another PBS (2 ml). The tissue was treated with 1% sodium bicarbonate solution (300 μl) for 30 minutes, then the sodium bicarbonate solution was removed and washed / rinsed with PBS solution (2 × 2 ml). The tissue was suspended in Solvable reagent (500 μl) and incubated at 95 ° C with melanin standard samples (prepared by suspending melanin in Solvable reagent to generate 0, 2.5, 5, 10, 25, 50 and 100 μg of melanin standards) for 24 hours. All incubated samples were centrifuged at 13000 rpm for 5 minutes, and the optical density of the supernatant was read / measured at 490 nm. The amount (μg) of melanin for each tissue sample was determined from the melanin standard sample calibration curve. The protein concentration of tissue samples was determined using a BCA protein assay kit (Pierce), and melanin content was standardized and expressed as melanin (μg) / protein (Table 1). The tissue viability of the results of the test compound administration / feed relative to the negative control and vehicle control was determined using a WST-1 kit. Tissue images were examined to assess the melanin-lightening ability of the test compound of the present invention compared to the negative control, vehicle control, and positive control, and cytotoxicity was assessed by microscopy (10 times magnification).

[0091] Table 1: Melanin content after treatment with compounds

[0092] Note: The compounds in Table 1 were prepared according to the method described in WO2018137683.

[0093] Melanoderm data results showed that compound 1 and lanosterol significantly reduced the melanin content and had a certain effect in treating / improving pigmentation.

[0094] Example 3 Age spot effect testing method

[0095] The formulation and preparation method used are shown below.

[0096] Compound 1: 10 mg

[0097] PEG400: 0.45g

[0098] Tween 80: 0.025g

[0099] PVP: 0.025g

[0100] HP-β-CD: 0.475g

[0101] Water: 8.515 mL

[0102] The specific preparation steps are as follows:

[0103] In a glass container containing compound 1, 0.45 g of PEG400, 0.025 g of Tween 80, and 0.025 g of PVP were added and stirred at 45° C. for 15 minutes; then, 0.475 g of HP-β-CD and 8.515 mL of water were added and stirred at 45° C. for 15 minutes; finally, ultrasonication was performed using a Covaris ultrasonic disruptor for 20 minutes to obtain the above formulation.

[0104] Experimental method: Volunteers with age spots on their faces were recruited and the composition of the present invention was applied to the age spots once every morning, noon, and evening. Facial photographs were taken on the first and 60th day after application of the composition of the present invention.

[0105] Figure 1 (left) is a partial facial photograph of a patient on day 1 of application of the composition of the present invention; Figure 1 (right) is a partial facial photograph 60 days after application of the composition of the present invention. It can be seen that the patient's age spots were significantly improved and reduced after 60 days of application of the composition of the present invention.

[0106] Although the present invention has been described in detail above using general explanations, specific embodiments, and experiments, it will be apparent to those skilled in the art that modifications and improvements may be made based on the present invention. Therefore, such modifications and improvements, which do not depart from the spirit of the present invention, are intended to be within the scope of protection claimed herein.

Claims

1. Use of a steroidal compound in the preparation of a product for preventing or treating skin pigmentation-related conditions or anti-aging-related products, characterized in that: The steroidal compound is a compound having a structure as represented by formula (I), or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound having a structure as represented by formula (I); wherein R is H, D, alkyl, sulfate, phosphate, alkylsilyl, benzyl, or -C(O)-X; X is selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroalkyl or alkyl; The aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroalkyl, alkylsilyl and alkyl groups in R and X are optionally substituted with 1, 2, 3 or 4 substituents which are the same or different; The substituent is selected from D, halogen, hydroxyl, thiol, amino, cyano, nitro, carboxyl, alkylcarbonyl, alkyl, haloalkyl, cycloalkyl, heterocyclic, aryl, arylalkyl, heteroaryl, carboxyl, R 1 R 2 NC(=O)- or R 1 R 2 NC(=NH)-NR 3 -; R 1 、R 2 and R 3 Each is independently selected from H, D or alkyl.

2. The use according to claim 1, wherein The steroid compound is a compound having a structure as represented by formula (II) or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound having a structure as represented by formula (II), wherein R is defined as in formula (I).

3. The use according to claim 1 or 2, wherein: R is H, D, C 1-6 Alkyl, sulfate, phosphate, C 1-6 Alkylsilyl, benzyl or -C(O)-X; X is selected from C 6-10 Aryl, C 2-9 Heteroaryl, C 3-8 Cycloalkyl, C 2-10 Heterocyclic group, C 1-6 Heteroalkyl or C 1-6 alkyl; R and X are described in C 6-10 Aryl, C 2-9 Heteroaryl, C 3-8 Cycloalkyl, C 2-10 Heterocyclic group, C 1-6 Heteroalkyl, C 1-6 Alkylsilyl or C 1-6 The alkyl group is optionally substituted with 1, 2, 3 or 4 substituents which may be the same or different; The substituent is selected from D, halogen, hydroxyl, thiol, amino, cyano, nitro, carboxyl, C 1-6 Alkylcarbonyl, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-8 Cycloalkyl, C 2-10 Heterocyclic group, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 2-9 Heteroaryl, carboxyl, R 1 R 2 NC(=O)- or R 1 R 2 NC(=NH)-NR 3 -; R 1 、R 2 and R 3 Each independently selected from H, D or C 1-6 alkyl.

4. The use according to any one of claims 1 to 3, characterized in that X is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, mercaptoethyl, aminomethyl, aminoethyl, aminopropyl, phenylmethyl, phenylethyl, imidazolylmethyl, carboxymethyl, carboxyethyl, methylthiomethyl, methylthioethyl, phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, cyclohexyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, cyclohexyl, tetrahydrofuranyl, dihydrofuranyl, cyclohex ... pentyl, dithiolanyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, furanyl, imidazolyl, 3-[4-(2-methyl-2-oxo-4-yl)-1-oxo-4-oxo-3 ... -isoxazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl, tetrazolyl, triazolyl, 2-thienyl, 3-thienyl, pyrazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl, 1,3,5-triazine yl, benzimidazolyl, benzofuranyl, benzothiophenyl, indolyl, purinyl, quinolinyl, isoquinolinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, C with H2NC(=O)-substituent 1-3 Alkyl or C with H2NC(=NH)-NH-substituent 1-3 alkyl.

5. The use according to any one of claims 1 to 4, characterized in that The substituent is selected from -D, halogen, hydroxy, amino, cyano, nitro, carboxyl, C 1-6 Alkylcarbonyl, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-8 Cycloalkyl, C 2-9 Heterocyclic group, C 6-10 Aryl or C 2-9 Heteroaryl.

6. The use according to any one of claims 1 to 5, characterized in that The substituents are selected from -D, -F, -Cl, -Br, hydroxyl, amino, cyano, carboxyl, formyl, acetyl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, trifluoromethyl, difluoromethyl, phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H- pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, furanyl, imidazolyl, 3-isoxazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, Tetrazolyl, triazolyl, 2-thienyl, 3-thienyl, pyrazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl, 1,3,5-triazinyl, benzimidazolyl, benzofuranyl, benzothiophene yl, indolyl, purinyl, quinolyl, isoquinolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl or [1,2,4]triazolo[1,5-a]pyridinyl.

7. The use according to any one of claims 1 to 6, characterized in that X is selected from any of the following groups:

8. The use according to claim 1, characterized in that The compound represented by the formula I is selected from any one of the following compounds:

9. The use according to any one of claims 1 to 8, characterized in that The product is selected from medicines, health products and skin care products; and / or The skin pigmentation-related condition is selected from one or more of chloasma, pregnancy spots, butterfly spots, age spots, café au lait spots and freckles; and / or The anti-aging product is a product related to anti-skin aging.

10. Use of a composition for preparing a product for preventing or treating skin pigmentation-related conditions or anti-aging-related products, characterized in that the composition comprises a steroid compound as defined in any one of claims 1 to 9, and one or more pharmaceutically or cosmetically acceptable carriers, excipients, diluents, adjuvants, or vehicles. Preferably, the skin pigmentation-related condition is selected from one or more of chloasma, chloasma, chloasma, age spots, café au lait spots and freckles; and / or The anti-aging product is an anti-skin aging product.

11. The use according to any one of claims 1 to 10, wherein the dosage form of the product is a solution, emulsion, suspension, cream, ointment, gel or patch.

12. A method for preventing or treating skin pigmentation-related conditions or anti-aging, comprising administering to a subject a steroidal compound as defined in any one of claims 1 to 9 or a composition as defined in the application of claim 10 or 11; Preferably, the skin pigmentation-related condition is selected from one or more of chloasma, chloasma, chloasma, age spots, café au lait spots and freckles; and / or The anti-aging product is an anti-skin aging product.

Images